EXOMIND & rTMS Research Library
Recent systematic reviews have examined transcranial magnetic stimulation for inattention, hyperactivity and impulsivity. Results are promising, but the evidence is not yet strong enough to position TMS as a first-line ADHD treatment.
Why this finding matters
Attention and executive-function difficulties can affect work, school, relationships and confidence. Early TMS findings are encouraging, but the evidence does not support replacing established ADHD assessment and treatment with brain stimulation.
Research Spotlight
Promising—not yet first-line
- Systematic review
- Symptom domains studied
- Minor adverse events reported
- More trials needed
What the evidence suggests
A 2025 systematic review and meta-analysis reported improvements across inattention, hyperactivity/impulsivity and total ADHD symptom scores, with generally minor adverse events. More recent syntheses continue to describe domain-specific potential.
What this could mean for you
For people seeking help with focus or executive functioning, neuropsychological formulation remains essential. EXOMIND may be discussed as an emerging option only after considering diagnosis, sleep, mood, medication, learning history and functional demands.
A careful, individualized next step
Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.
Clarify the right pathway first
We can help distinguish diagnostic assessment, standard ADHD care and an emerging brain-optimization pathway so you can make an informed decision.
Book a Consultation Explore the related Calgary service
Related Calgary service: ADHD Assessment Calgary EXOMIND rTMS Calgary
Study citation
Fu et al. Efficacy and safety of transcranial magnetic stimulation for attention-deficit/hyperactivity disorder: systematic review and meta-analysis. PMID: 39829146.
View the original record on PubMed
Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.